Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Clay Ferguson

Family Medicine Nashville, AR Medical Doctor

NPI 1518962968 CMS profile 1004521

114 N Main St, Nashville, AR 71852

Open in the dashboard

General payments

$771

43 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Clay Ferguson of Nashville, AR is reported in the CMS Open Payments database as having received $771 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $134 8
2024 General $227 12
2023 General $384 21
2022 General $14 1
2020 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Clay Ferguson
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Clay Ferguson were reported at $134. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Clay Ferguson Family Medicine median Middle half National median
2019 $0 $150 $41–$543 $163
2020 $12 $120 $32–$415 $114
2021 $0 $137 $35–$551 $132
2022 $14 $137 $37–$512 $149
2023 $384 $149 $42–$545 $160
2024 $227 $156 $44–$560 $164
2025 $134 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Teva Pharmaceuticals USA, Inc. $193 9 payments
  2. Otsuka America Pharmaceutical, Inc. $192 12 payments
  3. MIMEDX Group, Inc. $135 6 payments
  4. Lundbeck LLC $70 5 payments
  5. Sumitomo Pharma America, Inc. $67 4 payments
  6. Abbott Laboratories $34 2 payments
  7. SK Life Science, Inc. $27 1 payment
  8. Novartis Pharmaceuticals Corporation $26 2 payments
  9. KCI USA, Inc $15 1 payment
  10. Inogen, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $666 42 payments
  2. Education $106 1 payment
Products named General payments · program years 2020–2025
  1. REXULTI Psychiatry $192 12 payments
  2. REXULTI Psychiatry $70 5 payments
  3. Austedo XR $69 4 payments
  4. GEMTESA $67 4 payments
  5. FreeStyle Libre 3 $34 2 payments
  6. ENTRESTO $26 2 payments
  7. AUSTEDO $19 4 payments
  8. ACTIV.A.C. $15 1 payment
  9. V.A.C. DERMATAC $15 1 payment
  10. SNAP $15 1 payment
  11. Other $28 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 439 drugs

Part D claims

90,895

Median for Family Practice: 1,826

Drug cost

$5,160,615

Median for Family Practice: $120,094

Branded share of claims

22.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 2,897 $885,377
Nuplazid Pimavanserin Tartrate Brand 60 $146,767
Xarelto Rivaroxaban Brand 491 $141,776
Gemtesa Vibegron Brand 531 $134,781
Farxiga Dapagliflozin Propanediol Brand 274 $87,772
Ingrezza Valbenazine Tosylate Brand 12 $84,623
Rexulti Brexpiprazole Brand 109 $81,271
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 357 $80,609
Januvia Sitagliptin Phosphate Brand 255 $80,199
Linzess Linaclotide Brand 140 $79,274

The 10 drugs with the highest cost, of 439 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$254,045

Medicare's payments for the services billed

Medicare patients

1,201

Average age 76

Services billed

4,966

713 women, 488 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 58%
Alzheimer's or dementia 48%
Diabetes 45%
Arthritis 41%
Heart failure 36%
Ischemic heart disease 31%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $89
  • Lundbeck LLC $30
$119 109 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record